CVMP Adopted Positive Opinion For Marketing Application For Cimalgex
11 12월 2010 - 3:20AM
Dow Jones News
The Committee for Medicinal Products for Veterinary Use, or
CVMP, said Friday it adopted by consensus a positive opinion for a
marketing authorization application for Cimalgex, cimicoxib, from
Vetoquinol SA (VETOF), for the treatment of pain and inflammation
associated with osteoarthritis, and the management of
peri-operative pain due to orthopedic or soft tissue surgery, in
dogs.
MAIN FACTS:
-Committee adopted by consensus a positive opinion for a
marketing authorization application for Comfortis, spinosad, from
Eli Lilly and Company Ltd (LLY), for the treatment and prevention
of flea infestations in dogs.
-Committee adopted by consensus a positive opinion for a
marketing authorization application for ACTIVYL, indoxacarb, from
Intervet International BV, for the treatment and prevention of flea
infestations in cats and dogs.
-Committee adopted by consensus a positive opinion for a
marketing authorization application for Purevax Rabies from MERIAL,
for the active immunization of cats to prevent mortality due to
rabies infection.
-Committee adopted by consensus a positive opinion for a
marketing authorization application for Melosus, meloxicam, from
CP-Pharma Handelsgesellschaft mbH, for the alleviation of
inflammation and pain in both acute and chronic musculo-skeletal
disorders in dogs and the alleviation of inflammation and pain in
chronic musculo-skeletal disorders in cats.
-Committee adopted by consensus a positive opinion for a type II
variation application for Zulvac 8 Ovis and ZOLVIX.
-Committee also adopted by consensus a negative opinion for a
type II variation application for Masivet.
-Committee agreed scientific advice concerning the establishment
of an MRL for horses as a follow-up request to advice previously
given.
-Committee also agreed scientific advice for review of dossier
requirements in line with the MUMS guidelines for an immunological
product for sheep and goats.
-By Tapan Panchal, Dow Jones Newswires. Tel +44(0)207-842 9448,
tapan.panchal@dowjones.com
Vetoquinol (PK) (USOTC:VETOF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Vetoquinol (PK) (USOTC:VETOF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
